Clinicopathological characteristics | Fresh frozen tumors N (%) | Paraffin-embedded tumors N (%) |
---|---|---|
Age at diagnosis | Â | Â |
   Mean | 69 | 70 |
   Range | 42 to 93 | 23 to 98 |
Tumor size | Â | Â |
   T1 | 18 (27) | 93 (42) |
   T2 | 38 (58) | 91 (41) |
   N/A | 10 (15) | 36 (16) |
Node status | Â | Â |
   N0 | 16 (24) | 83 (38) |
   N+ | 37 (56) | 78 (35) |
   N/A | 13 (20) | 59 (27) |
ER status | Â | Â |
   Positive | 52 (79) | 193 (88) |
   Negative | 3 (5) | 9 (4) |
   N/A | 11 (17) | 18 (8) |
PR status | Â | Â |
   Positive | 46 (70) | 160 (73) |
   Negative | 9 (14) | 41 (19) |
   N/A | 11 (17) | 19 (9) |
HER2 status | Â | Â |
   Positive | 2 (3) | 18 (8) |
   Negative | 35 (53) | 157 (71) |
   N/A | 29 (44) | 45 (20) |
BRCA2 mutation status | Â | Â |
   Positive | 3 (5) | 5 (2) |
   Negative | 7 (11) | 12 (5) |
   N/A | 56 (85) | 203 (92) |
Histology | Â | Â |
   DCIS | 1 (2) | 4 (2) |
   Invasive cancer in combination with DCIS | 14 (21) | 47 (21) |
   Invasive cancer | 43 (65) | 130 (59) |
   N/A | 8 (12) | 39 (18) |
NHG | Â | Â |
   I | 2 (3) | 15 (7) |
   II | 17 (26) | 98 (44) |
   III | 19 (29) | 85 (39) |
   N/A | 28 (42) | 22 (10) |
Metastases | Â | Â |
   Yes | 16 (24) | 46 (21) |
   No | 39 (59) | 123 (56) |
   N/A | 11 (17) | 51 (23) |
Follow-up time (years) | Â | Â |
   Mean | 5.3 | 4.6 |
   Range | 0.20 to 15 | 0.04 to 15 |
Adjuvant chemotherapy | Â | Â |
   Yes | 6 (9) | 21 (10) |
   No | 51 (77) | 159 (72) |
   N/A | 9 (14) | 40 (18) |
Adjuvant endocrine therapy | Â | Â |
   Yes | 37 (56) | 120 (55) |
   No | 20 (30) | 66 (30) |
   N/A | 9 (14) | 34 (15) |
Post-operative radiotherapy | Â | Â |
   Yes | 30 (45) | 85 (39) |
   No | 28 (42) | 96 (44) |
   N/A | 8 (12) | 39 (18) |
Surgery | Â | Â |
   Mastectomy | 58 (88) | 178 (81) |
   Lumpectomy | 1 (2) | 12 (5) |
   No surgery | 0 (0) | 2 (1) |
   N/A | 7 (11) | 28 (13) |